Shuttle Pharmaceuticals (SHPH) Competitors $0.64 -0.04 (-5.87%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends SHPH vs. INDP, BCDA, CYCN, RDHL, VCNX, MYNZ, GNPX, MBIO, BCLI, and AYTUShould you be buying Shuttle Pharmaceuticals stock or one of its competitors? The main competitors of Shuttle Pharmaceuticals include Indaptus Therapeutics (INDP), BioCardia (BCDA), Cyclerion Therapeutics (CYCN), RedHill Biopharma (RDHL), Vaccinex (VCNX), Mainz Biomed (MYNZ), Genprex (GNPX), Mustang Bio (MBIO), Brainstorm Cell Therapeutics (BCLI), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical products" industry. Shuttle Pharmaceuticals vs. Indaptus Therapeutics BioCardia Cyclerion Therapeutics RedHill Biopharma Vaccinex Mainz Biomed Genprex Mustang Bio Brainstorm Cell Therapeutics Aytu BioPharma Shuttle Pharmaceuticals (NASDAQ:SHPH) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, community ranking, earnings, risk and institutional ownership. Which has more volatility and risk, SHPH or INDP? Shuttle Pharmaceuticals has a beta of -1.7, meaning that its share price is 270% less volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Do analysts prefer SHPH or INDP? Indaptus Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 806.18%. Given Indaptus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Indaptus Therapeutics is more favorable than Shuttle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shuttle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer SHPH or INDP? In the previous week, Shuttle Pharmaceuticals had 4 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 4 mentions for Shuttle Pharmaceuticals and 0 mentions for Indaptus Therapeutics. Shuttle Pharmaceuticals' average media sentiment score of 0.77 beat Indaptus Therapeutics' score of 0.00 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Shuttle Pharmaceuticals Positive Indaptus Therapeutics Neutral Which has preferable earnings & valuation, SHPH or INDP? Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioShuttle PharmaceuticalsN/AN/A-$6.59M-$4.15-0.15Indaptus TherapeuticsN/AN/A-$15.42M-$1.71-0.55 Does the MarketBeat Community favor SHPH or INDP? Indaptus Therapeutics received 13 more outperform votes than Shuttle Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformShuttle PharmaceuticalsN/AN/AIndaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33% Is SHPH or INDP more profitable? Indaptus Therapeutics' return on equity of -177.27% beat Shuttle Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Shuttle PharmaceuticalsN/A -583.02% -258.92% Indaptus Therapeutics N/A -177.27%-141.06% Do insiders & institutionals have more ownership in SHPH or INDP? 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 39.6% of Shuttle Pharmaceuticals shares are held by company insiders. Comparatively, 29.5% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryIndaptus Therapeutics beats Shuttle Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Shuttle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SHPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SHPH vs. The Competition Export to ExcelMetricShuttle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.35M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.1510.5990.1317.20Price / SalesN/A196.061,117.09117.05Price / CashN/A57.1643.1037.85Price / Book0.325.094.784.78Net Income-$6.59M$151.83M$120.31M$225.60M7 Day Performance-6.51%-2.14%-1.92%-1.23%1 Month Performance-26.51%-4.56%13.65%0.46%1 Year PerformanceN/A8.87%28.34%15.24% Shuttle Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SHPHShuttle Pharmaceuticals1.1388 of 5 stars$0.64-5.9%N/AN/A$2.35MN/A-0.155News CoverageGap DownINDPIndaptus Therapeutics2.868 of 5 stars$0.96-4.0%$8.50+785.4%-49.6%$9.79MN/A-0.586BCDABioCardia3.3021 of 5 stars$2.09+0.5%$25.00+1,096.2%-79.8%$9.58M$71,000.00-0.5016Analyst ForecastShort Interest ↓Positive NewsGap UpCYCNCyclerion Therapeutics0.6403 of 5 stars$3.53+2.9%N/A-22.2%$9.57M$194,000.000.0030Gap DownRDHLRedHill Biopharma0.4365 of 5 stars$7.41-0.4%N/A-99.2%$9.49M$3.71M0.00210Gap DownVCNXVaccinex0.9775 of 5 stars$3.65-1.1%N/A-85.7%$9.49M$570,000.00-0.0740Positive NewsMYNZMainz Biomed2.507 of 5 stars$4.73-11.8%$120.00+2,437.0%-85.7%$9.47M$917,203.00-0.0730News CoverageGap UpHigh Trading VolumeGNPXGenprex3.9233 of 5 stars$1.05-9.5%$10.00+852.4%-89.1%$8.93MN/A0.0020Gap UpMBIOMustang Bio1.9623 of 5 stars$0.19-5.1%$2.00+975.3%-86.3%$8.89MN/A-0.12100Positive NewsBCLIBrainstorm Cell Therapeutics3.9873 of 5 stars$1.55+6.9%$30.00+1,835.5%-21.2%$8.84MN/A-0.3040Gap UpAYTUAytu BioPharma0.8898 of 5 stars$1.40-2.8%N/A-52.9%$8.61M$81M-1.17160Positive News Related Companies and Tools Related Companies INDP Alternatives BCDA Alternatives CYCN Alternatives RDHL Alternatives VCNX Alternatives MYNZ Alternatives GNPX Alternatives MBIO Alternatives BCLI Alternatives AYTU Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SHPH) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shuttle Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shuttle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
